COMPANY
AT WEP CLINICAL, WE ARE WITH EVERY PATIENT
We are a Pharmaceutical Services Provider that specializes in Drug Development Programs, Treatment Access Solutions and Market Access and Commercialization
About Us
Leadership Team
Global Coverage
Partnerships
Testimonials
Careers
SERVICES
Core Services
Expanded Access Programs
Post-Trial Access
Post-Approval Named Patient
Market Access Solutions
Clinical Trial Services
Clinical Trial Sourcing
Home Health Solutions
WEP 3PL
Adjacent Services
Project Management
Real World Data
Pharmacovigilance
Advocacy
RESOURCES
WEP INSIGHTS
BLOG & MEDIA
CASE STUDIES

Expanded Access
Post-Approval Named Patient
Market Access
Nursing Solutions
View All Case Studies
BLOG

Early Access Programs – What to Consider as a Patient
Read More
What is a Compassionate Use Program?
Read More
View All Blog Posts
NEWS

WEP CLINICAL HAS PARTNERED WITH PLUSULTRA PHARMA TO SUPPLY HYFTOR® TO PATIENTS IN EU/EEA COUNTRIES (WITH THE EXCEPTION OF GERMANY)
Read More
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH GERON CORPORATION FOR AN EXPANDED ACCESS PROTOCOL FOR IMETELSTAT
Read More
View All News

COMPANY
AT WEP CLINICAL, WE ARE WITH EVERY PATIENT
We are a Pharmaceutical Services Provider that specializes in Drug Development Programs, Treatment Access Solutions and Market Access and Commercialization
About Us
Leadership Team
Global Coverage
Partnerships
Testimonials
Careers
SERVICES
Core Services
Expanded Access Programs
Post-Trial Access
Post-Approval Named Patient
Market Access Solutions
Clinical Trial Services
Clinical Trial Sourcing
Home Health Solutions
WEP 3PL
Adjacent Services
Project Management
Real World Data
Pharmacovigilance
Advocacy
RESOURCES
WEP INSIGHTS
BLOG & MEDIA
CASE STUDIES

Expanded Access
Post-Approval Named Patient
Market Access
Nursing Solutions
View All Case Studies
BLOG

Early Access Programs – What to Consider as a Patient
Read More
What is a Compassionate Use Program?
Read More
View All Blog Posts
NEWS

WEP CLINICAL HAS PARTNERED WITH PLUSULTRA PHARMA TO SUPPLY HYFTOR® TO PATIENTS IN EU/EEA COUNTRIES (WITH THE EXCEPTION OF GERMANY)
Read More
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH GERON CORPORATION FOR AN EXPANDED ACCESS PROTOCOL FOR IMETELSTAT
Read More
View All News

ResourcesWep Clinical2024-09-19T13:32:19+01:00

Resources

All Resources|
Real World Data Resources|
Market Access Resources|
Expanded Access Resources|
Open Label Extensions Resources|
Post-Approval Patient Programs Resources|

Sample Regulatory Assessment for Treatment Access Program

4th December 2024/

Sponsor Considerations for Post-Trial Access

11th November 2024/

Harnessing Real-World Data for Market Access Success

24th July 2024/

Step-by-step EAP Management Process

16th July 2024/

Navigating Asset Transitions that include EAPs

9th May 2024/

Building Stakeholder Engagement Through EAPs

4th March 2024/

International Recognition Procedure

19th December 2023/

Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (VPAG)

13th December 2023/

Managing Patient Requests For Investigational Medicines

8th December 2023/

EU Health Technology Assessments

2nd November 2023/

Value of Real World Data in EAP

21st July 2022/

PA-NPP Product Uptake By Country

25th November 2021/

EAP Versus OLE Study

20th January 2021/

Sponsor Considerations for EAPs

11th December 2020/

Expanded Access Policy Templates

5th March 2020/

NEED MORE INFORMATION?

Facebook Linkedin

Privacy & Cookie Policy
Terms & Conditions
Ethics and Compliance

Menu

Privacy & Cookie Policy
Terms & Conditions
Ethics and Compliance